Acelyrin, Inc. announced that Mina Kim to it?s Board of Directors. Ms. Kim brings more than 20 years of operational and leadership experience across a range of industries including synthetic biology, immunotherapy, renewable energy, and aviation. Ms. Kim played a pivotal role in ACELYRIN?s initial public offering and has served as ACELYRIN?s Chief Legal and Administrative Officer since November 2022.

Prior to that, she served as Chief Legal Officer and Head of Corporate Development at Zymergen, Inc., where she led the company?s corporate strategy and business development teams and built its legal team. She also oversaw Zymergen?s 2021 IPO process and the company?s eventual sale to Ginkgo Bioworks. In addition to Ms. Kim?s appointment, Shephard (Shep) Mpofu, M.D., MRCP, FRCP, who most recently served as it?s Senior Vice President of Development, has been promoted to the role of Chief Medical Officer, Gil Labrucherie, who serves as it?s Chief Financial Officer, has been named Chief Business Officer in addition to Chief Financial Officer, and Sanam Pangali, who most recently served as it?s Senior Vice President, Corporate Legal, has been promoted to Chief Legal Officer and Head of People.

Mina Kim has served as the Chief Legal and Administrative Officer of ACELYRIN, INC. since 2022. From 2020 to 2022, Ms. Kim was the Chief Legal Officer and Head of Corporate Development at Zymergen, Inc., where she oversaw corporate strategy, business development, corporate & SEC reporting, intellectual property, litigation and employment, compliance, regulatory, public policy, and sustainability. She led Zymergen?s 2021 IPO process and later sale to Ginkgo Bioworks.

Prior to Zymergen, Ms. Kim served as Senior Vice President of Corporate Strategy and General Counsel at Atara Biotherapeutics. Before Atara, Ms. Kim was General Counsel at Sunrun where she led the 2015 IPO. Earlier in her career she was Vice President, Legal at BBAM, LLC, General Counsel of Fly Leasing, Assistant General Counsel at Williams-Sonoma, and an Associate at the law firm Davis Polk & Wardwell.

She holds a JD from Harvard Law School and a BA in History from Dartmouth College. Shep Mpofu has served as Senior Vice President, Development and Translational Sciences of ACELYRIN, INC. since October 2023. Prior to ACELYRIN he spent nearly 20 years at Novartis AG, where he most recently served as Chief Medical Officer for its Gene Therapy Franchise.

At Novartis he held positions of increasing responsibility in the immunology, rheumatology and dermatology franchises, which culminated with global leadership of clinical development for canakinumab and secukinumab. He is a UK General Medical Council Board-certified rheumatologist, who previously practiced at several institutions in the UK. He is a Fellow of the Royal College of Physicians UK, and he obtained his MB.Ch.B (Bachelor of Medicine and Bachelor of Surgery degrees) from the Godfrey Huggins School of Medicine at the University of Zimbabwe.

Gil has served as the Chief Financial Officer of ACELYRIN, INC. since 2022. He was previously Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics where he led a team of more than 150 professionals in financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management. Prior to that he was the Senior Vice President and General Counsel at Nektar, Vice President of Corporate Development at E2open, Inc. and Senior Director of Corporate Development at AltaVista Company.

He began his career as corporate counsel at Wilson Sonsini Goodrich & Rosati. Gil holds a JD from the University of California Berkeley School of Law and a BA from the University of California Davis. He is also a CFA charterholder.

Sanam Pangali has served as Senior Vice President, Corporate Legal of ACELYRIN, INC. since October 2023 and previously served as Vice President, Corporate Legal. Prior to joining ACELYRIN in 2022, she served as General Counsel, Vice President and Corporate Secretary at Snapdocs, Inc., a technology company in the mortgage lending space, from 2020 to 2021. Before that, she served as Senior Director & Associate General Counsel at Principia Biopharma Inc. through its September 2020 acquisition by Sanofi.

Earl ier in her career, she led the corporate and commercial contracting legal functions at Sunrun Inc., from 2016 to 2019 and prior to that was Director & Assistant General Counsel at affiliates TerraForm Power and SunEdison Inc. from 2013 to 2016, spanning mergers and acquisitions, project finance and development. Ms. Pangali began her legal career as a Senior Associate at Morrison & Foerster LLP for six years working in the firm?s Business and Finance practice groups, advising clients in capital markets, venture capital, mergers and acquisitions, project finance and corporate governance matters. She holds a JD from the University of Pennsylvania Carey Law School and a BA in Political Science, with a Minor in Economics, from the University of California, San Diego.